North America Regional Guide

Legal Status Overview: United States

Federal Law

Psilocybin is a Schedule I controlled substance under the US Controlled Substances Act (CSA). This means the federal government classifies it as having no accepted medical use and a high potential for abuse. Federal law applies at airports, across state lines, and on federal land, regardless of state or local laws. Possession, distribution, and manufacture are federal criminal offences.

Oregon: Regulated Therapeutic Access

Oregon passed Measure 109 in 2020, creating the first state-regulated psilocybin services programme in the US. Adults 21+ can access supervised psilocybin sessions at licensed service centres operated by licensed facilitators under Oregon Health Authority (OHA) oversight. Services launched in 2023. Key points: no take-home product; on-site consumption only; no medical diagnosis required; costs vary widely (typically several hundred to several thousand USD). See our dedicated Oregon guide for full details.

Colorado: Decriminalisation Plus Regulated Access

Colorado's Proposition 122 (Natural Medicine Health Act, passed 2022) both decriminalised personal possession, use, and home growing of psilocybin for adults 21+ and created a licensed "natural medicine healing centre" framework. Colorado's law also covers DMT, ibogaine, and mescaline from non-peyote sources. Licensed healing centres began operating in 2024. Unlike Oregon, personal possession (within limits) is decriminalised even outside licensed centres. Sale outside the licensed framework remains illegal. See our dedicated Colorado guide.

City-Level Decriminalisation

A growing number of US cities have deprioritised or decriminalised psilocybin possession at the local level. These include:

• Denver, Colorado (2019): First city to decriminalise personal psilocybin possession.
• Oakland and Santa Cruz, California (2019–2020): Decriminalised personal possession of all natural psychedelics.
• Washington, DC (Initiative 81, 2020): Made enforcement of psilocybin personal possession laws the lowest priority.
• Ann Arbor, Michigan; Somerville, Cambridge, Northampton, Massachusetts; Seattle, Washington; Detroit, Michigan: Passed decriminalisation resolutions.

Decriminalisation does not create a legal market. There is no legal source to purchase psilocybin in these cities unless a licensed therapeutic framework also exists.

All Other US States

In states without specific decriminalisation legislation, psilocybin possession is a criminal offence under both state and federal law. Penalties vary by state but can include felony charges for possession in some jurisdictions.

Legal Status Overview: Canada

Psilocybin is a Schedule III substance under Canada's Controlled Drugs and Substances Act (CDSA). Possession, production, and trafficking are criminal offences. However, two legal pathways exist for medical access:

• Section 56 Exemptions: The Minister of Health may grant individual exemptions for medical or scientific purposes. Health Canada has granted these to terminally ill patients and to therapists for training.
• Special Access Programme (SAP): Allows licensed physicians to apply for psilocybin access for specific patients with serious conditions when conventional treatments have failed. Not a general public access route.

British Columbia received a federal exemption in 2023 permitting personal possession of some drugs; the scope with respect to psilocybin specifically should be verified with current sources. See our dedicated Canada guide.

Legal Status Overview: Mexico

Mexico's drug law situation is complex. Psilocybin mushrooms are listed as a prohibited psychotropic substance under Mexico's General Health Law. However, Article 195 of the same law has historically been interpreted to provide some protection for indigenous use of traditional plant medicines — including teonanácatl (psilocybin mushrooms) — as part of recognised indigenous ceremonial practices in communities such as the Mazatec people of Oaxaca.

For non-indigenous visitors attending ceremonies in places like Huautla de Jiménez, legal protection is ambiguous and not guaranteed. Enforcement has historically been minimal in traditional ceremonial contexts, but this is not a legal framework and is subject to change. Do not assume any specific legal protection without consulting a Mexican lawyer.

Native Species in North America

North America has a rich native diversity of psilocybin-containing species. Key species by region:

Pacific Northwest (USA and Western Canada)

• Psilocybe cyanescens (Wavy Cap): Very common in wood chip mulch in urban and suburban areas. Fruits prolifically in autumn. One of the most potent widely available species; contains high psilocybin and psilocin concentrations. Blue-green bruising when handled.
• Psilocybe azurescens (Flying Saucer Mushroom): Found in coastal dune grass (particularly Ammophila grass) along a narrow band of the Oregon and Washington coast. Extremely potent — among the highest psilocybin concentrations of any known species. Fruits in autumn.
• Psilocybe baeocystis (Bottle Cap / Olive Cap): Found in wood chips, lawns, and peat in the Pacific Northwest. Moderate potency.
• Psilocybe stuntzii: Another wood chip and lawn species of the Pacific Northwest. Less common, moderate potency.

Southeastern United States

• Psilocybe cubensis: The most widely cultivated species globally. In the wild, it fruits on cattle dung in subtropical grasslands across the Gulf Coast states (Florida, Texas, Louisiana, Mississippi) and throughout Central America. Moderate potency; highly variable.
• Panaeolus cyanescens (Wavy Cap / Blue Meanies): Found in dung-enriched tropical and subtropical grasslands, often co-occurring with cubensis. More potent per gram than most cubensis strains.
• Panaeolus cinctulus: Widespread in fertilised lawns and composted areas across the US; one of the most commonly encountered species in suburban settings.

Mexico and Central America

• Psilocybe mexicana: The species originally studied by R. Gordon Wasson and Albert Hofmann. Native to Mexico's highland grasslands. Forms sclerotia (truffles) when grown in certain conditions.
• Psilocybe cubensis: Widespread across Mexico and Central America, particularly in cattle-grazing areas.
• Psilocybe caerulescens (Landslide Mushroom): Grows in disturbed soil and sugarcane debris. Used in traditional Mazatec ceremonies.
• Psilocybe zapotecorum: Found in muddy or marshy areas in Mexican highlands. Traditional ceremonial use.

Lookalike Warning

Several toxic or deadly mushroom species can be confused with psilocybin-containing species by inexperienced foragers. Most dangerous:

• Galerina marginata: A deadly wood-rotting species containing amatoxins, which can cause fatal liver failure. Can grow alongside or be confused with Psilocybe cyanescens and Psilocybe stuntzii. Has caused fatalities. Always check gill attachment, spore print (Galerina: rust-brown), and presence of a ring on the stem.
• Conocybe filaris: Another amatoxin-containing lawn species that resembles Panaeolus cinctulus.

Expert identification is essential. Blue bruising when handled is a strong indicator but not definitive proof of psilocybin content — always cross-reference multiple identification features and use quality reference materials or seek expert verification.

Cultural and Historical Context

Psilocybin mushroom use has deep roots in North American indigenous traditions. In Mexico, the Mazatec, Zapotec, and other peoples of Oaxaca have practised veladas (night ceremonies) with teonanácatl for centuries; the tradition was brought to Western attention by R. Gordon Wasson's 1957 Life magazine article. The healer Maria Sabina became internationally known as a result, though she later expressed ambivalence about this attention and the commercialisation that followed.

Respecting this cultural heritage — and not appropriating or commercialising indigenous knowledge without community consent — is an active ethical discussion within the psychedelic community. Organisations such as the Chacruna Institute work specifically on indigenous data sovereignty and cultural equity in the psychedelic medicine space.

Research and Clinical Programmes

North America hosts the world's most active psilocybin clinical research ecosystem:

• Johns Hopkins Centre for Psychedelic and Consciousness Research (Baltimore, MD): Arguably the most prolific clinical research site globally. Published landmark studies on psilocybin for depression, addiction (alcohol, tobacco), and end-of-life distress.
• NYU Langone Centre for Psychedelic Medicine (New York, NY): Major trials on alcohol use disorder and cancer-related distress.
• UC Berkeley Centre for the Science of Psychedelics: Neuroscience, policy, and basic science research.
• MAPS (Multidisciplinary Association for Psychedelic Studies): Primarily MDMA-focused but has funded psilocybin research and trains therapists.